Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 24, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's ordinary shares, executed under authority granted at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on share capital movements.
- Shares Repurchased: 3,650,000 ordinary shares of 25 pence each.
- Repurchase Date: June 24, 2008.
- Price per Share: 1,124.514 pence.
- Treasury Shares Held: 474,194,158 shares (representing 8.95% of total voting rights).
- Shares in Issue: 5,298,368,549 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the company's share capital through the cancellation of 3,650,000 repurchased shares. Consequently, the total number of shares in issue stands at 5,298,368,549. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,298,368,549) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (474,194,158) and its impact on total voting rights (8.95%).
- Note that this filing does not contain financial performance data; refer to Form 20-F for revenue and profit metrics.